2675 related articles for article (PubMed ID: 15852361)
21. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
[TBL] [Abstract][Full Text] [Related]
22. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
Potters L; Cha C; Oshinsky G; Venkatraman E; Zelefsky M; Leibel S
Cancer J Sci Am; 1999; 5(5):301-6. PubMed ID: 10526671
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer.
Heymann JJ; Benson MC; O'Toole KM; Malyszko B; Brody R; Vecchio D; Schiff PB; Mansukhani MM; Ennis RD
J Clin Oncol; 2007 Jan; 25(1):77-84. PubMed ID: 17194907
[TBL] [Abstract][Full Text] [Related]
25. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension.
Dattoli M; Wallner K; True L; Cash J; Sorace R
Urology; 2007 Feb; 69(2):334-7. PubMed ID: 17320673
[TBL] [Abstract][Full Text] [Related]
26. PSA bounce after prostate brachytherapy with or without neoadjuvant androgen deprivation.
McGrath SD; Antonucci JV; Fitch DL; Ghilezan M; Gustafson GS; Vicini FA; Martinez AA; Kestin LL
Brachytherapy; 2010; 9(2):137-44. PubMed ID: 19850537
[TBL] [Abstract][Full Text] [Related]
27. Six year experience of external beam radiotherapy, brachytherapy boost with a 1Ci (192)Ir source, and neoadjuvant hormonal manipulation for prostate cancer.
Izard MA; Haddad RL; Fogarty GB; Rinks A; Dobbins T; Katelaris P
Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):38-47. PubMed ID: 16904516
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma: influence of prostatic acid phosphatase.
Dattoli M; Wallner K; True L; Cash J; Sorace R
Cancer; 2003 Feb; 97(4):979-83. PubMed ID: 12569596
[TBL] [Abstract][Full Text] [Related]
29. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
30. Early prostate-specific antigen (PSA) kinetics following prostate carcinoma radiotherapy: prognostic value of a time-and-PSA threshold model.
Cavanaugh SX; Kupelian PA; Fuller CD; Reddy C; Bradshaw P; Pollock BH; Fuss M
Cancer; 2004 Jul; 101(1):96-105. PubMed ID: 15221994
[TBL] [Abstract][Full Text] [Related]
31. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
[TBL] [Abstract][Full Text] [Related]
32. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer.
D'Amico AV; Saegaert T; Chen MH; Renshaw AA; George D; Oh W; Kantoff PW
Cancer; 2002 Jul; 95(2):275-80. PubMed ID: 12124826
[TBL] [Abstract][Full Text] [Related]
33. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK
Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941
[TBL] [Abstract][Full Text] [Related]
34. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
Urology; 2004 Oct; 64(4):754-9. PubMed ID: 15491715
[TBL] [Abstract][Full Text] [Related]
35. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of adjuvant intermittent endocrine therapy following neoadjuvant endocrine therapy and external beam radiation therapy in men with locally advanced prostate cancer.
Yamanaka H; Ito K; Naito S; Tsukamoto T; Usami M; Fujimoto H; Matsuoka N; Fukui I; Harada M; Ohashi Y; Kotake T; Kakizoe T
Prostate; 2005 Apr; 63(1):56-64. PubMed ID: 15468166
[TBL] [Abstract][Full Text] [Related]
37. Biochemical response after 3-d conformal radiotherapy of localized prostate cancer to a total dose of 66 gy 4-year results.
Wachter-Gerstner N; Wachter S; Goldner G; Nechvile E; Pötter R
Strahlenther Onkol; 2002 Oct; 178(10):542-7. PubMed ID: 12386785
[TBL] [Abstract][Full Text] [Related]
38. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
Gondi V; Deutsch I; Mansukhani M; O'Toole KM; Shah JN; Schiff PB; Katz AE; Benson MC; Goluboff ET; Ennis RD
Urology; 2007 Mar; 69(3):541-6. PubMed ID: 17382161
[TBL] [Abstract][Full Text] [Related]
39. Short-course androgen ablation combined with external-beam radiation therapy and low-dose-rate permanent brachytherapy in early-stage prostate cancer: a matched subset analysis.
Sylvester J; Blasko JC; Grimm PD; Meier R; Cavanagh W
Mol Urol; 2000; 4(3):155-9;discussion 161. PubMed ID: 11062369
[TBL] [Abstract][Full Text] [Related]
40. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
Sarosdy MF
Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
